CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics


CASI Pharmaceuticals, Inc. (CASI)

Today's Latest Price: $3.46 USD

0.07 (2.06%)

Updated Jan 19 4:00pm

Add CASI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

CASI Stock Summary

  • For CASI, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • CASI's price/sales ratio is 36.03; that's higher than the P/S ratio of 93.13% of US stocks.
  • As for revenue growth, note that CASI's revenue has grown 318.48% over the past 12 months; that beats the revenue growth of 97.84% of US companies in our set.
  • Stocks that are quantitatively similar to CASI, based on their financial statements, market capitalization, and price volatility, are ADMP, MTBC, JAGX, TEUM, and XXII.
  • Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.

CASI Stock Price Chart Interactive Chart >

Price chart for CASI

CASI Price/Volume Stats

Current price $3.46 52-week high $3.60
Prev. close $3.39 52-week low $1.15
Day low $3.39 Volume 642,500
Day high $3.60 Avg. volume 552,627
50-day MA $2.56 Dividend yield N/A
200-day MA $2.13 Market Cap 428.85M

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI Pharmaceuticals Inc that investors may wish to consider to help them evaluate CASI as an investment opportunity.

CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference

ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Dr. Wei-Wu He, Chairman and Chief…

PR Newswire | January 8, 2021

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug Evaluation, a division of the China National Medical Products Association, has granted Breakthrough Therapy Designation ("Breakthrough Designation") to its partner Juventas Cell Therapy Ltd. for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). CASI has co-commercial rights to CNCT19 and is a shareholder of Juventas.

Yahoo | December 23, 2020

CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

ROCKVILLE, Md., and BEIJING, Dec. 16, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces the appointment of Weihao Xu to the…

PR Newswire | December 16, 2020

Is CASI A Good Stock To Buy Now?

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

Yahoo | December 12, 2020

CASI: Raising target price on pipeline progress

By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT After some disruption to business in the first quarter from the pandemic, CASI Pharmaceuticals (NASDAQ:CASI) again raised its target for Evomela sales in 2020. Management believes sales are likely meet or exceed $14 million in 2020, compared with its previous guidance of $10 million. In addition, the Company completed its planned

Yahoo | November 30, 2020

Read More 'CASI' Stories Here

CASI Price Returns

1-mo 24.46%
3-mo 116.25%
6-mo 78.35%
1-year N/A
3-year -15.40%
5-year 387.32%
YTD 17.29%
2020 -4.53%
2019 -23.13%
2018 23.69%
2017 182.61%
2016 19.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7049 seconds.